Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2020.05.105
Abstract: BACKGROUND Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone. OBJECTIVE To provide longer-term efficacy and safety data for bimekizumab from… read more here.
Keywords: week; phase extension; extension study; bimekizumab ... See more keywords